AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Glutathione S-transferase Mu 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q03013

UPID:

GSTM4_HUMAN

Alternative names:

GST class-mu 4; GST-Mu2; GSTM4-4; Leukotriene C4 synthase GSTM4

Alternative UPACC:

Q03013; A8K765; Q05465; Q32NC1; Q4JNT8; Q6FH87

Background:

Glutathione S-transferase Mu 4 (GST Mu 4), known by alternative names such as GST-Mu2 and Leukotriene C4 synthase GSTM4, plays a crucial role in detoxification processes. It achieves this by facilitating the conjugation of reduced glutathione to a broad spectrum of hydrophobic electrophiles. Notably, it catalyzes the formation of leukotriene C4 from leukotriene A4 and the transformation of 13(S),14(S)-epoxy-docosahexaenoic acid into maresin conjugate in tissue regeneration 1 (MCTR1), a lipid mediator with significant anti-inflammatory and proresolving properties.

Therapeutic significance:

Understanding the role of Glutathione S-transferase Mu 4 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.